Taiwan Liposome Co., Ltd.

Taiwan Liposome Co., Ltd.

Taiwan Liposome Co., Ltd.

Overview
Date Founded

1997

Headquarters

11/F-1,3 Yuanqu Street,Nangang District,Taipei, Taipei City 115 03

Type of Company

Public

Employees (Worldwide)

101 - 250

Industries

Biotechnology
Medical Support Services
Hospitals & Patient Services

Company Description

Taiwan Liposome Co., Ltd. engages in the authorized cooperative development of special medicine as well as new formulation and prescription drugs. The firm offers pain management, ophthalmology, and oncology related drugs based on lipid drug delivery system. It also provides royalties and biotechnology services. The company was founded by Chi Lung Hung on November 10, 1997 and is headquartered in Taipei, Taiwan.

Contact Data
Trying to get in touch with decision makers at Taiwan Liposome Co., Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

President

Executive Director, Clinical Affairs-TLC United States

Chief Financial Officer & Director-Administration

Chief Medical Officer

Chief Business Officer

President, TLC Japan

Senior Director, Product Development Division

Director, Quality Assurance Division

Director, Portfolio & Strategy Division

Board of Directors

Founder at Taiwan Liposome Co., Ltd.

Venture Partner, Harbinger USA at Harbinger Venture Management

Former Vice President at OBI Pharma, Inc.

Director at National Federation of Certified Public Accountant Assoc ROC

President & General Manager at CHO Pharma, Inc.

M.B.A. Representing Burrill Life Sciences Capital Fund III at TLC Biopharmaceuticals, Inc.

Former Chief Investment Officer at Yuanta Securities Co., Ltd.

Director, Representing Chang Xiang Investment Company, Ltd at Taiwan Liposome Co., Ltd.

Paths to Taiwan Liposome Co., Ltd.
Potential Connections via
Relationship Science
You
Taiwan Liposome Co., Ltd.
Owners & Shareholders
Details Hidden

Karst Peak Capital is an active manager which aims to achieve absolute returns by focusing on public and private equity investments throughout Asia and Australasia. The firm builds concentrated portfolio of long-term holdings in the consumer, healthcare, and technology sectors.

Details Hidden

Karst Peak Capital is an active manager which aims to achieve absolute returns by focusing on public and private equity investments throughout Asia and Australasia. The firm builds concentrated portfolio of long-term holdings in the consumer, healthcare, and technology sectors.

Recent Transactions
Details Hidden

Taiwan Liposome Co., Ltd. issued USD American Depositary Shares

Details Hidden

purchases Taiwan Liposome Co., Ltd.

Transaction Advisors
Underwriter

Advised onTaiwan Liposome Co., Ltd. issued USD American Depositary Shares

Underwriter

Advised onTaiwan Liposome Co., Ltd. issued USD American Depositary Shares

Underwriter

Advised onTaiwan Liposome Co., Ltd. issued USD American Depositary Shares

Legal Advisor

Advised onTaiwan Liposome Co., Ltd. issued USD American Depositary Shares

Legal Advisor

Advised onTaiwan Liposome Co., Ltd. issued USD American Depositary Shares

Legal Advisor

Advised onTaiwan Liposome Co., Ltd. issued USD American Depositary Shares

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Clients

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company was founded by Jing Lou and Dan Lou in 1993 and is headquartered in Shenyang, China.

SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone’s ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California.

Key Stats and Financials As of 2019
Market Capitalization
$182M
Total Enterprise Value
$158M
Earnings Per Share
$-0.4
EBITDAMargin
-356.82%
Enterprise Value / Sales
23.24x
TEVNet Income
-6.02x
Debt TEV
0.1x
Three Year Compounded Annual Growth Rate Of Revenue
71.21%
Five Year Compounded Annual Growth Rate Of Revenue
16.87%
Revenue
$6.8M
Net Profit
$-26.3M
EBITDA
$-24.3M
Total Debt
$16.6M
Total Equity
$23.5M
Investors
Details Hidden

Founder at Taiwan Liposome Co., Ltd.

Details Hidden

TTY Biopharm Co. Ltd. engages in the manufacture and distribution of pharmaceutical drugs. Its products include Lipo-Dox, Lonsurf, UFUR, TS-1, Brosym, Colimycin, Algitab, and Alginos. It operates through the following segments: Oncology Business Unit, Health Care Unit, Anti-Infection Business Unit, Domestic Cardiovascular and Gastrointestinal Drugs Business Unit, China Medicine Business Unit, and Other. The company was founded on July 22, 1960 and is headquartered in Taipei, Taiwan.

Details Hidden

IBTM's investment strategy focuses on early- to mid- stage high-tech firms. Their objective is to create growth and create competitive advantage. They seek to maximize returns for their venture capital fund investors and employ a prudent investment strategy.Geographically they concentrate on firms operating in Taiwan, the US, and Europe in segments such as semiconductors, optoelectronics, networking, computers, biotechnology, and software. They typically take minority stakes under 20% in each investee firm. Their investment size ranges from USD 0.3 million to USD 10 million.

Suppliers
Baxter International, Inc. Pharmaceuticals | Deerfield, IL

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2011 sales of $13.9 billion and has approximately 48,500 employees.

Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Evonik Industries AG Industrial Machinery & Manufacturing | Essen, Deu

Evonik Industries AG is a holding company, which engages in the manufacture of specialty chemical products. It operates through the following segments: Nutrition and Care, Resource Efficiency, Performance Materials, Services, and Other Operations. The Nutrition and Care segment produces specialty chemicals, principally for use in consumer goods for daily needs, and in animal nutrition and healthcare products. The Resource Efficiency segment supplies materials and specialty additives for environment-friendly and energy-efficient system solutions for the automotive, paints, coatings, adhesives, construction industries, and other sectors. The Performance Materials segment manufacture polymer materials and intermediates, mainly for the rubber, plastics, and agriculture industries. The Services segment comprises site management, utilities, waste management, technical, process technology, engineering, and logistics services for the chemical segments and external customers. The Other Operation segment consists management holding company, strategic research, and hidden reserves and liabilities. The company was founded in 1919 and is headquartered in Essen, Germany.

Competitors
AbbVie, Inc. Pharmaceuticals - North Chicago, IL

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Pacira Biosciences, Inc. Pharmaceuticals - Parsippany, NJ

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Flexion Therapeutics, Inc. Pharmaceuticals - Burlington, MA

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Taiwan Liposome Co., Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Taiwan Liposome Co., Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Taiwan Liposome Co., Ltd..